New figures reveal a devastating shortfall in the rollout of the long-acting HIV prevention drug lenacapavir, with experts warning current plans are insufficient to change the course of the pandemic.
A groundbreaking HIV prevention injection offering six months of protection with lenacapavir will be available in 120 lower-income countries by 2027 through a landmark access agreement.
The European Medicines Agency has approved a groundbreaking HIV prevention drug, marking a significant step forward in public health. Learn more about this medical milestone.